Konrad H. Stopsack

May 10, 2024 | medrxiv.org | Jonathan Mitchell |Patrick Shea |Konrad H. Stopsack |Niedzica Camacho

J.M., N.C., O.B., R.D., A.N., A.O., A.A., Q.W., L.A.-D., R.M., B.D., K.C., S.P., M.A.F. are current employees and/or stockholders of AstraZeneca. A.W.Z receives grant funding and consulting fees from AstraZeneca. L.A.M. is on the advisory board and holds equity interest in Convergent Therapeutics. A.M. is a former employee of AstraZeneca and current employee of GSK and a stockholder of AstraZeneca and GSK. C.H. was an employee and stockholder of AZ at the time of study.

Mar 15, 2024 | nature.com | Yiwen Zhang |Konrad H. Stopsack |Mingyang Song

AbstractMultivitamin use is common among cancer patients. Whether post-diagnostic multivitamin supplementation is beneficial for prostate cancer survival is largely unknown, and some evidence even suggests potential harm. We prospectively assessed post-diagnostic multivitamin use in relation to prostate cancer survival among 4756 men with nonmetastatic prostate cancer at diagnosis in the Health Professionals Follow-up Study (1986–2016).

Mar 1, 2024 | onlinelibrary.wiley.com | Yiwen Zhang |Konrad H. Stopsack |Mingyang Song |Lorelei A. Mucci

CONFLICT OF INTEREST STATEMENT L.A.M. received research funding from Astra Zeneca and Janssen; was a consultant to Bayer; serves on the SAB and has equity in Convergent Therapeutics. None of these activities were related to the work under review. The other authors declare no potential conflicts of interest. Supporting Information Filename Description ijc34898-sup-0001-supinfo.pdfPDF document, 625.9 KB Data S1. Supporting information. REFERENCES 1, , , et al.